CBS and hyperlipidemia: In hyperlipidemic rats, Sal A treatment caused enhanced activities of hepatic CBS (+2.2-fold vs. hyperlipidemia group, p < 0.01) and CSE (+7% vs. hyperlipidemia group, p < 0.05), which was accompanied by a reduction in plasma homocysteine levels (−17% vs. hyperlipidemia group, p < 0.05) and an increase in hepatic cysteine concentrations (+33% vs. hyperlipidemia group, p < 0.05).